Suppr超能文献

《世事变迁》——晚期及复发性卵巢癌的腹腔镜肿瘤细胞减灭术:一家转诊中心对108例患者的经验

"Things Have Changed"-Laparoscopic Cytoreduction for Advanced and Recurrent Ovarian Cancer: The Experience of a Referral Center on 108 Patients.

作者信息

Ceccaroni Marcello, Roviglione Giovanni, Bruni Francesco, Dababou Susan, Venier Martina, Zorzi Carlotta, Salgarello Matteo, Ruffo Giacomo, Alongi Filippo, Gori Stefania, Driul Lorenza, Uccella Stefano, Barra Fabio

机构信息

Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally-Invasive Pelvic Surgery, International School of Surgical Anatomy, IRCCS Sacro Cuore "Don Calabria" Hospital, Negrar, 37024 Verona, Italy.

Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, 37129 Verona, Italy.

出版信息

Cancers (Basel). 2023 Dec 6;15(24):5726. doi: 10.3390/cancers15245726.

Abstract

OBJECTIVE

To report the feasibility of laparoscopic cytoreduction surgery for primary and recurrent ovarian cancer in a select group of patients.

METHODS

A retrospective analysis was conducted on a cohort of patients with FIGO stage IIIA-IV advanced ovarian cancer who underwent laparoscopic primary debulking surgery (PDS), interval debulking surgery (IDS), or secondary debulking surgery (SDS) between June 2008 and January 2020. The primary endpoint was achieving optimal cytoreduction, defined as residual tumor less than 1 cm. Secondary endpoints included evaluating surgical complications and long-term survival, assessed at three-month intervals during the initial two years and then every six months.

RESULTS

This study included a total of 108 patients, among whom, 40 underwent PDS, 44 underwent IDS, and 24 underwent SDS. Optimal cytoreduction rates were found to be 95.0%, 97.7%, and 95.8% for the PDS, ISD, and SDS groups, respectively. Early postoperative complications (<30 days from surgery) occurred in 19.2% of cases, with 7.4% of these cases requiring reintervention. One patient died following postoperative respiratory failure. Late postoperative complications (<30 days from surgery) occurred in 9.3% of cases, and they required surgical reintervention only in one case. After laparoscopic optimal cytoreduction with a median follow-up time of 25 months, the overall recurrence rates were 45.7%, 38.5%, and 39.3% for PDS, ISD, and SDS, respectively. The three-year overall survival rates were 84%, 66%, and 63%, respectively, while the three-year disease-free survival rates were 48%, 51%, and 71%, respectively.

CONCLUSIONS

Laparoscopic cytoreduction surgery is feasible for advanced ovarian cancer in carefully selected patients, resulting in high rates of optimal cytoreduction, satisfactory peri-operative morbidity, and encouraging survival outcomes. Future studies should focus on establishing standardized selection criteria and conducting well-designed investigations to further refine patient selection and evaluate long-term outcomes.

摘要

目的

报告在一组特定患者中,腹腔镜细胞减灭术治疗原发性和复发性卵巢癌的可行性。

方法

对2008年6月至2020年1月期间接受腹腔镜初次肿瘤细胞减灭术(PDS)、中间肿瘤细胞减灭术(IDS)或二次肿瘤细胞减灭术(SDS)的FIGO IIIA-IV期晚期卵巢癌患者队列进行回顾性分析。主要终点是实现最佳细胞减灭,定义为残留肿瘤小于1厘米。次要终点包括评估手术并发症和长期生存率,在最初两年每三个月评估一次,之后每六个月评估一次。

结果

本研究共纳入108例患者,其中40例行PDS,44例行IDS,24例行SDS。PDS、ISD和SDS组的最佳细胞减灭率分别为95.0%、97.7%和95.8%。术后早期并发症(术后<30天)发生率为19.2%,其中7.4%的病例需要再次干预。1例患者术后因呼吸衰竭死亡。术后晚期并发症(术后>30天)发生率为9.3%,仅1例需要手术再次干预。腹腔镜最佳细胞减灭术后,中位随访时间为25个月,PDS、ISD和SDS的总复发率分别为45.7%、38.5%和39.3%。三年总生存率分别为84%、66%和63%,三年无病生存率分别为48%、51%和71%。

结论

对于精心挑选的晚期卵巢癌患者,腹腔镜细胞减灭术是可行的,可实现较高的最佳细胞减灭率,围手术期发病率令人满意,生存结果令人鼓舞。未来的研究应专注于建立标准化的选择标准,并进行精心设计的调查,以进一步优化患者选择并评估长期结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfc/10741886/4028de2ee39f/cancers-15-05726-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验